Interaction between paliperidone extended release and TS-1®, an oral anticancer drug containing a 5-fluorouracil derivative, in a schizophrenic patient
Norio Yasui-Furukori, Kojiro Hashimoto, Kazutoshi Kubo, Tetsu Tomita Department of Neuropsychiatry, Graduate School of Medicine, Hirosaki University, Hirosaki, Japan Abstract: Until now there has been no information available on drug interaction between paliperidone and TS-1®, an oral an...
Guardado en:
Autores principales: | Yasui-Furukori N, Hashimoto K, Kubo K, Tomita T |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/ca6b542bbbdb401981d02d6907e26979 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Role of paliperidone extended-release in treatment of schizoaffective disorder
por: Carla M Canuso, et al.
Publicado: (2010) -
The role of paliperidone extended release for the treatment of bipolar disorder
por: Marino J, et al.
Publicado: (2012) -
Effects of paliperidone extended release on hostility among Thai patients with schizophrenia
por: Jariyavilas A, et al.
Publicado: (2017) -
The social functional outcome of being naturalistically treated with paliperidone extended-release in patients with schizophrenia
por: Nakagawa R, et al.
Publicado: (2015) -
Cost effectiveness and cost utility of the noncoding blood glucose meter CONTOUR® TS
por: Przemyslaw Holko, et al.
Publicado: (2011)